Who are R-DA-EPOCH-21 + auto-SCT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SOX Chemotherapy, FEC, TAC chemotherapy, chemotherapy of mFOLFOX6 or FOLFIRI, CEV chemotherapy, Dose dense AC followed by T + trastuzumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/r-da-epoch-21-auto-sct.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

R-DA-EPOCH-21 + auto-SCT — Competitive Intelligence Brief

R-DA-EPOCH-21 + auto-SCT (R-DA-EPOCH-21 + auto-SCT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy regimen. Area: Oncology.

phase 3 Chemotherapy regimen CD20 (rituximab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

R-DA-EPOCH-21 + auto-SCT (R-DA-EPOCH-21 + auto-SCT) — National Research Center for Hematology, Russia. R-DA-EPOCH-21 is a chemotherapy regimen that combines rituximab with the EPOCH chemotherapy regimen, followed by an autologous stem cell transplant.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
R-DA-EPOCH-21 + auto-SCT TARGET	R-DA-EPOCH-21 + auto-SCT	National Research Center for Hematology, Russia	phase 3	Chemotherapy regimen	CD20 (rituximab)
SOX Chemotherapy	SOX Chemotherapy	The First Affiliated Hospital with Nanjing Medical University	marketed	Combination chemotherapy regimen
FEC	FEC	Hoffmann-La Roche	marketed	Combination chemotherapy regimen
TAC chemotherapy	TAC chemotherapy	Agendia	marketed	Chemotherapy regimen (combination)
chemotherapy of mFOLFOX6 or FOLFIRI	chemotherapy of mFOLFOX6 or FOLFIRI	Xu jianmin	marketed	Combination chemotherapy regimen	Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin)
CEV chemotherapy	CEV chemotherapy	Sun Yat-sen University	marketed	Combination chemotherapy regimen
Dose dense AC followed by T + trastuzumab	Dose dense AC followed by T + trastuzumab	Agendia	marketed	Chemotherapy regimen with monoclonal antibody	HER2 receptor (trastuzumab component); DNA/microtubules (chemotherapy components)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy regimen class)

National Research Center for Hematology, Russia · 2 drugs in this class
Asan Medical Center · 1 drug in this class
AstraZeneca · 1 drug in this class
CTI BioPharma · 1 drug in this class
Federation Francophone de Cancerologie Digestive · 1 drug in this class
Guiyang Medical University · 1 drug in this class
Japan Clinical Oncology Group · 1 drug in this class
PETHEMA Foundation · 1 drug in this class
Sixth Affiliated Hospital, Sun Yat-sen University · 1 drug in this class
Trans Tasman Radiation Oncology Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). R-DA-EPOCH-21 + auto-SCT — Competitive Intelligence Brief. https://druglandscape.com/ci/r-da-epoch-21-auto-sct. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab